Literature DB >> 15793105

Is in vitro antibiotic combination more effective than single-drug therapy against anthrax?

Abed Athamna1, Muhammad Athamna, Aburashed Nura, Eli Shlyakov, Darrin J Bast, David Farrell, Ethan Rubinstein.   

Abstract

Antibiotic combinations are used to enhance antibacterial efficacy and to prevent the development of resistance. We have tested a possible synergistic effect of several antibacterial combinations on Bacillus anthracis. The in vitro activities of antibiotic combinations against two strains of B. anthracis, strain Sterne and the Russian anthrax vaccine strain STi, were tested by the fractional inhibitory concentration (FIC) method, derived from the MICs of the agents in combination, and by measuring the rate of bacterial killing over time by several antibiotic combinations. The FIC results showed that synergism against both B. anthracis strains was observed only with the combination of rifampin and clindamycin. The telithromycin-amoxicillin combination showed synergism against strain Sterne only. All other combinations were either indifferent or antagonistic. The results of the bacterial time-kill study demonstrated indifferent effects for all combinations. These in vitro results demonstrate the difficulties in obtaining synergistic combinations of antibiotics against B. anthracis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15793105      PMCID: PMC1068588          DOI: 10.1128/AAC.49.4.1323-1325.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Reduced release of pneumolysin by Streptococcus pneumoniae in vitro and in vivo after treatment with nonbacteriolytic antibiotics in comparison to ceftriaxone.

Authors:  Annette Spreer; Holger Kerstan; Tobias Böttcher; Joachim Gerber; Alexander Siemer; Gregor Zysk; Timothy J Mitchell; Helmut Eiffert; Roland Nau
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

2.  Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test.

Authors:  R L White; D S Burgess; M Manduru; J A Bosso
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

3.  Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone.

Authors:  E W ter Braak; P J de Vries; K P Bouter; S G van der Vegt; G C Dorrestein; J W Nortier; A van Dijk; R P Verkooyen; H A Verbrugh
Journal:  Am J Med       Date:  1990-07       Impact factor: 4.965

4.  Antimicrobial susceptibility testing of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods.

Authors:  M Jasmine Mohammed; Chung K Marston; Tanja Popovic; Robbin S Weyant; Fred C Tenover
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

Review 5.  Anthrax as a biological weapon, 2002: updated recommendations for management.

Authors:  Thomas V Inglesby; Tara O'Toole; Donald A Henderson; John G Bartlett; Michael S Ascher; Edward Eitzen; Arthur M Friedlander; Julie Gerberding; Jerome Hauer; James Hughes; Joseph McDade; Michael T Osterholm; Gerald Parker; Trish M Perl; Philip K Russell; Kevin Tonat
Journal:  JAMA       Date:  2002-05-01       Impact factor: 56.272

6.  Update: Investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2001-11-02       Impact factor: 17.586

7.  In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity.

Authors:  A Athamna; M Massalha; M Athamna; A Nura; B Medlej; I Ofek; D Bast; E Rubinstein
Journal:  J Antimicrob Chemother       Date:  2003-12-19       Impact factor: 5.790

8.  Selection of Bacillus anthracis isolates resistant to antibiotics.

Authors:  A Athamna; M Athamna; N Abu-Rashed; B Medlej; D J Bast; E Rubinstein
Journal:  J Antimicrob Chemother       Date:  2004-06-17       Impact factor: 5.790

9.  Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings.

Authors:  Daniel B Jernigan; Pratima L Raghunathan; Beth P Bell; Ross Brechner; Eddy A Bresnitz; Jay C Butler; Marty Cetron; Mitch Cohen; Timothy Doyle; Marc Fischer; Carolyn Greene; Kevin S Griffith; Jeannette Guarner; James L Hadler; James A Hayslett; Richard Meyer; Lyle R Petersen; Michael Phillips; Robert Pinner; Tanja Popovic; Conrad P Quinn; Jennita Reefhuis; Dori Reissman; Nancy Rosenstein; Anne Schuchat; Wun-Ju Shieh; Larry Siegal; David L Swerdlow; Fred C Tenover; Marc Traeger; John W Ward; Isaac Weisfuse; Steven Wiersma; Kevin Yeskey; Sherif Zaki; David A Ashford; Bradley A Perkins; Steve Ostroff; James Hughes; David Fleming; Jeffrey P Koplan; Julie L Gerberding
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

  9 in total
  6 in total

1.  Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits.

Authors:  Shay Weiss; Zeev Altboum; Itai Glinert; Josef Schlomovitz; Assa Sittner; Elad Bar-David; David Kobiler; Haim Levy
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

2.  Clindamycin Protects Nonhuman Primates Against Inhalational Anthrax But Does Not Enhance Reduction of Circulating Toxin Levels When Combined With Ciprofloxacin.

Authors:  Nicholas J Vietri; Steven A Tobery; Donald J Chabot; Susham Ingavale; Brandon C Somerville; Jeremy A Miller; Chris W Schellhase; Nancy A Twenhafel; David P Fetterer; Christopher K Cote; Christopher P Klimko; Anne E Boyer; Adrian R Woolfitt; John R Barr; Mary E Wright; Arthur M Friedlander
Journal:  J Infect Dis       Date:  2021-02-03       Impact factor: 5.226

3.  Antibacterial Activities of Selected Cameroonian Plants and Their Synergistic Effects with Antibiotics against Bacteria Expressing MDR Phenotypes.

Authors:  Stephen T Lacmata; Victor Kuete; Jean P Dzoyem; Simplice B Tankeo; Gerald Ngo Teke; Jules R Kuiate; Jean-Marie Pages
Journal:  Evid Based Complement Alternat Med       Date:  2012-02-28       Impact factor: 2.629

4.  Bacteriostatic antimicrobial combination: antagonistic interaction between epsilon-viniferin and vancomycin against methicillin-resistant Staphylococcus aureus.

Authors:  Dayang Fredalina Basri; Lee Wee Xian; Nur Indah Abdul Shukor; Jalifah Latip
Journal:  Biomed Res Int       Date:  2014-03-24       Impact factor: 3.411

Review 5.  Alternative pre-approved and novel therapies for the treatment of anthrax.

Authors:  Breanne M Head; Ethan Rubinstein; Adrienne F A Meyers
Journal:  BMC Infect Dis       Date:  2016-11-03       Impact factor: 3.090

6.  Diffusible signal factor (DSF) quorum sensing signal and structurally related molecules enhance the antimicrobial efficacy of antibiotics against some bacterial pathogens.

Authors:  Yinyue Deng; Amy Lim; Jasmine Lee; Shaohua Chen; Shuwen An; Yi-Hu Dong; Lian-Hui Zhang
Journal:  BMC Microbiol       Date:  2014-02-27       Impact factor: 3.605

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.